Emma J Mickley

Emma J Mickley, PhD, vice-president, corporate business development, Aesica Pharmaceuticals

Articles

September 2nd 2014

Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.

Latest Updated Articles

Published: October 11th 2024 | Updated: October 18th 2024

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 10th 2024 | Updated: September 18th 2024

CPHI Milan Announces 2024 CPHI Pharma Award Finalists

Published: February 23rd 2024 | Updated: December 22nd 2024

Europa Perspectives: Helping to Navigate the Regulatory System

Published: December 13th 2024 | Updated: December 22nd 2024

FDA Creates CDER Center for Real-World Evidence Innovation

Close-up of a microscope lens examining microarray slides, a crucial tool in genomic research and medical diagnostics | Image Credit: © Varunee - Stock.Adobe.com

Published: December 5th 2024 | Updated: December 22nd 2024

Leveraging Advancements in Bioanalytical Testing

Lipid nanoparticle siRNA antiviral delivery system, 3D illustration | Image Credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com

Published: December 7th 2024 | Updated: December 22nd 2024

Exploring Opportunities for LNP Delivery in mRNA

About Us

Advertise

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777